INTRODUCTION
The Fas receptor, designated as APO-1 or CD95, is a 48-kD transmembrane glycoprotein belonging to the tumor necrosis factor receptor (TNFR) and nerve-growth superfamily, and has the potential action of mediating apoptotic signals after ligation with Fas ligand (FasL) or agonistic anti-Fas monoclonal antibodies (MoAb) (1) (2) (3) (4) (5) . Fas is expressed in a variety of tissues and hematopoietic normal or leukemic cells. Therefore, Fas-mediated apoptosis has been suggested to play a crucial role not only in activated-induced cell death of normal Tcells but also probably in neoplastic cells which express Fas (6-7).
The Fas gene found by Itoh and Nagata et al. (8) maps in chromosome 10q 24.1 and consists of 9 exons encoding extracellular (EC), transmembrane (TM), and intracytoplasmic (IC) domains. The Fas gene, moreover, encodes mainly two types of mRNA transcripts, full-length Fas mRNA, which is translated into membrane Fas isoform (mFas), which is in turn anchored on the cell-membrane by the TM domain, and alternatively spliced mRNA lacking exon 6 TMB&$Fas mRNA, which is translated into soluble Fas isoform (sFas) which lacks the TM domain. (9, 10) Not only mFas but also sFas can provide protection from Fas-mediated apoptosis in vivo through the decoy mechanism, which interferes with ligation between mFas and FasL via a mechanism similar to that of soluble TN FR (11, 12) .
Aberrant or defective mFas proteins caused by somatic mutation of the Fas gene or by an unknown control mechanism have been widely studied in relation to possible involvement in oncogenesis, evolution, and progression of tumours (13 (19) . encountered ATL cases with heterogeneous expression of mFas, varying from defective to markedly high, and with high serum levels of sFas (26) . At present, little is known about neoplasms from the viewpoint of the membrane and soluble isoforms of Fas.
In this paper, we review clinical and oncological significance of quantitatively and qualitatively aberrant expression of the membrane and soluble isoforms of Fas in ATL on the basis of our recent studies published elsewhere (20, (25) (26) (27) .
On the other hand, up-regulation of mFas and unbalanced production of Fas isoforms have been noted in a few malignancies and some ATL cell lines, implying that not only mFas but also sFas is involved in apoptosis of tumour cells (20) (21) .
ATL is derived from an uncontrolled clonal expansion of T-cells, probably via transactivation mechanisms of pX gene products of human T-cell leukemia virus type-1 (HTLV-1) integrated into the genome Like IL-2R, which is highly expressed on ATL cells due to transactivation by pX proteins (22, 23) , mFas is also abundantly expressed (24, 25) , however despite up-regulation of mFas, the cells can survive and form tumours which are associated with extremely poor prognosis. Recently, we have in vivo via its decoy function, the serum sFas level also should be considered to understand the Fasmediated apoptosis in blood.
As shown in Fig. 1 , ATL cells derived from about 90% of patients with ATL express not only mFas but also sFas at 2 to 5 fold higher density than normal controls, i.e. 3470 mFas molecules/cell and 1.54 + 0.45 ng/ml sFas. ATL cell lines more abundantly express only mFas, with about 3 to 10 fold increased density, but are defective in sFas. These isoforms can be measured using flow cytometric quantitaitve assays and enzyme linked immunosorbent assays. mFas expressed by malignant cells is actually functional at least in vitro after triggering by agonistic anti-Fas MoAb and recombinant FasL (26) . This means that ATL cells expressing mFas are in a primed state in vivo for apoptosis via Fas, which is probably important for tumor manifestation.
On the other hand, about 10% of ATL patients have no detectable mFas on the cell surface, but have a high sFas level in their sera, with no significant correlation between the mFas and sFas levels. Either mFas or sFas, and frequently both, in ATL cells are usually up-regulated and have the potential to receive the signal from the ligand.
(11) sFas level, but not mFas level, is related to clinical tumor biology.
The findings about aberrant Fas isoform expression described above suggest that high tumor burden such as reflected by large lymph node (LN) and high count of ATL cells in blood and highly malignant behaviour manifested by serum lactate dehydrogenase (LDH) activity, hypercalcemia and poor prognosis of 3-year survival rate (3y SR), is not related to mFas, as shown in Fig.2 . In contrast, as shown in Fig. 3 , a high sFas level is apparently associated with high tumor burden and poor malignant behaviour, especially an extremely short survival time, suggesting the decoy function of the sFas in blood. In ATL pathology, sFas thus apears to be more important than mFas in determing clinical aspects of the tumor, whereas the current opinion about solid tumors is that mFas is important.
More recently, there have been interesting studies that were instructive about the relationship between Fas isoforms and tumor biology. In these 
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studies, Natali et a1. (28) and Beletskaia et a1. (29) reported that the presence of alternative splicing isoforms, such as Fas with deleted TM, affected the cell resistance to Fas-mediated apoptosis, and that these isoforms were potentially able to neutralize anti-Fas or FasL.
(C) R T-PCR
The question then arises whether mFas status in ATL cells is flexible or not, and of the role of mFas in ATL biology. To understand these issues, it is convenient to examine our mFas-r.~gative ATL cells. First of all, it has been demonstarted that the ATL cells preserve normally both full-length and truncated Fas mRNAs, corresponding to mFas and sFas receptors (20, 25, 26) . Indeed, de novo fresh mFasnegative ATL cells come to express detectable mFas along with the change to dominant expression of the full-length mRNA and decrease of the truncated mRNA (Fig. 4) . A similar phenomen has also been reported in B-chronic lymphoid leukemia (CLL) cells, in which mFas is deficient or defective. Fresh CLL cells, which express low levels of mFas, are resistant to agonistic anti-Fas MoAb-mediated apoptosis (30) . After culturing cells in the presence of the mitogens, resulting in mFas expression on the cell surface, the cells become susceptible to agonistic anti-Fas.
On the other hand, there was a report that Fasnegative ATL cells from a patient were caused by the two isoforms, membrane or soluble, and that, consequently, overproduction of sFas is involved in the natural history of ATL.
(111) Mutated Fas in ATL
At first, mutation in Fas-encoding gene was reported in Ipr and Iprcg mice, which are models of auto-immune disease. These mice fail to eliminate self-reactive T-lymphocytes due to the mutation of Fas gene, resulting in the accumulation of a large number of non-malignant T-lymphocytes in the lymph nodes and spleen (6) . Recently, nucleotide sequence analysis of Fas transcripts has revealed the mutations probably resulting in congenital disorders in humans such as auto-immune lymphoproliferative syndrome (ALPS) (31) and Canale-Smith syndrome (32) , resembling the Ipr phenotype in mice with mutated Fas. These patients have defective Fas-mediated T-cell apoptosis associated with unique Fas gene mutation. More recently, even in acquired neoplasms such as myeloma, ALL, colon cancer, and hepatoma, mutations of Fas have also been demonstrated, implying that the tumorigenesis may be due to mutations of Fas. The membrane Fas status on these tumor cells varied from complete lack or deficiency to normal density. In some cases, although there was mFas lacking the intracytoplasmic signaling domain, no cell death could be induced through the Fas-signal system (33) . Such cases, however, are rare among the patients examined for Fas mutation (15) (16) (17) (18) so that the remaining majority of cases should be considered to have normal Fas genes. Now, there have been two reports about Fas mutations in ATL; one by Tamiya et a1. (17) and the other by our group. Out study showed a dominant negative defect in Fas-induced apoptosis in an ATL ceil line, KOB, and in the cell from which KOB was derived, de novo fresh ATL cells from a patient with ATL (27) . The cells were shown by flow cytometry to express mFas, although they showed resistance to induction of cell death by agonistic anti-Fas MoAb. Molecular analysis of the PCR products from not only the cell line but also the original de novo cells showed a 20-bp deletion in exon 9 in the mutated Fas mRNA, resulting in a frameshift and the generation of a premature stop codon at amino acid 239, as shown in Fig. 5 and 6 . A retrovirus-mediated gene transfer of the truncated Fas into Jurkat cells susceptible to Fas-mediated apoptosis rendered the cells resistant to the apoptosis. Such a mechanism is based on a dominant negative interference because of the effect of the endogenous wild-type Fas by the transfected mutant Fas ( Fig. 7 and 8 ). More interestingly, in this case ATL cells at the onset had the wild-type Fas gene in the lymph node and later an ATL subclone acquired a Fas mutation in the crisis phase leading to malignant behaviour, enabling the subclone to escape from apoptosis mediated by the Fas signalling system and proliferate in the body.
(IV) Conclusion
De novo fresh ATL cells and ATL cell lines heterogenously express mFas and sFas. Aberrant Fas isoform expression in ATL cells is instructive about the isoform roles in vivo and the significance of the isoforms in clinical oncology. Using these convenient "experiments of nature", further aspects of the complex relationship between tumorigenesis and Fas-mediated apoptosis regulated by various genes and their products will be elucidated in the near future.
